Chemical ID: CAS, formula and HS code database — Vitamin D3

Identification field	Record
CAS Registry Number	67-97-0
Product Name & IUPAC Name	Vitamin D3 / Cholecalciferol; IUPAC: (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
Chemical Formula	C27H44O
Synonyms & Trade Names	Cholecalciferol; Colecalciferol; Calciol; Activated 7-dehydrocholesterol; Vitamin D3. Compendial grades may be designated as Cholecalciferol USP, Cholecalciferol Ph. Eur., or Vitamin D3 feed grade. Trade names are grade-specific and concentration-dependent, particularly for oily concentrates, beadlet forms, and premixes.
HS Code & Customs Classification	2936.29 — Other vitamins and their derivatives under HS heading 2936. Neat cholecalciferol and vitamin D3 concentrates are classified according to national tariff schedules; formulated medicinal preparations or feed additive premixes may fall under separate classification provisions depending on concentration and end use.

Vitamin D3 (cholecalciferol, C₂₇H₄₄O, CAS 67-97-0, relative molecular mass 384.64 g/mol) is a secosteroid supplied in pure crystalline form and in stabilized feed-grade preparations. The crystalline material is normally a white to almost white crystalline powder or agglomerated crystals; slight yellowing may appear in aged or oxidized material and is treated as a degradation indicator, not as a routine release appearance. Odor is practically odorless. The melting point of the crystalline form is commonly observed over the range 82–85 °C, with the exact value influenced by polymorphic form and residual solvent content. A meaningful atmospheric boiling point is not assigned for cholecalciferol because thermal isomerization and decomposition products form before ebullition. Flash point is generally reported as not applicable for the solid; where a flash point appears on a safety data sheet, it is normally based on a solvent estimate rather than on the molten solid. Density is not a universal release constant: bulk and tapped density depend on particle size distribution, residual crystallinity, and the presence of flow agents or carriers.

For formulation, cholecalciferol is practically insoluble in water. Dissolution is achieved in ethanol, chloroform, acetone, fatty oils, medium-chain triglycerides, or other suitable nonpolar solvents. Aqueous processing does not begin as a simple aqueous solution; the material is incorporated as an oil solution, emulsion, or spray-dried dispersion. Analytical and processing solutions require protection from light and headspace oxygen. Solvents should be deoxygenated or blanketed with nitrogen when extended hold times are required. Solubility in vegetable oil is grade- and temperature-dependent; gentle heating can aid dispersion, but thermal input must be limited because isomerization and degradation may occur.

What Thermal, Photochemical, and Oxidative Stresses Dictate Storage Architecture?

Crystalline cholecalciferol is sensitive to light, oxygen, heat, and certain trace metal ions. The unsaturated triene system undergoes photochemically induced isomerization to pre-vitamin D3 and, under overirradiation, to toxisterols and other inactive products. Oxidation at the unsaturated system generates multiple polar degradation products. Degradation is accelerated by dissolved oxygen, elevated temperature, and trace iron or copper. Bulk stabilization therefore depends on dry nitrogen or argon blanketing, light-excluding equipment, and low-temperature storage. Contact with strong oxidizing agents, strong acids, and unprotected metal surfaces is controlled. The solid is not considered a meaningful flammability risk, but fine dust may form an explosible dust cloud if a sufficient airborne concentration is reached in milling or transfer operations, requiring dedicated dust extraction.

Specification and Quality Control Framework Across Crystalline and Stabilized Grades

Quality parameter	Crystalline pharmaceutical/food grade	Stabilized feed-grade beadlet/premix	Typical test basis
Appearance	White to almost white crystalline powder	Free-flowing beadlets or powder; off-white to pale yellow depending on coating	Visual examination against pharmacopoeial or customer reference
Assay / potency	Pharmacopoeial assay; may be expressed as 97.0–103.0% on a dried basis or as specified by the applicable monograph	Standardized to 100,000–1,000,000 IU/g or customer-specific IU/g level	HPLC-UV against a certified reference standard
Loss on drying	Low residual moisture; limit set by monograph	Moisture controlled to protect beadlet stability	USP 731 or Ph. Eur. equivalent
Related substances	Individual and total limits for pre-vitamin D3, trans-cholecalciferol, toxisterols, and oxidized species	Set to ensure batch-to-batch potency stability; may be less stringent than pharmaceutical-grade limits	HPLC area normalization with relative response factors
Residual solvents	Pharmacopoeial limits	Feed regulation or customer requirement	GC headspace
Heavy metals / arsenic	Pharmacopoeial general chapter limits	Regional feed-additive regulation	ICP-MS or atomic absorption
Microbial limits	Total aerobic count and absence of specified organisms as required	Total aerobic count and absence of Salmonella may be required	USP 61/62, ISO methods

The principal impurity sources in manufacture are incomplete conversion of 7-dehydrocholesterol, thermal equilibrium between pre-vitamin D3 and cholecalciferol, overirradiation leading to toxisterols, and oxygen ingress forming oxidized degradation products. In crystalline pharmaceutical-grade material, the monitored impurity profile normally includes 7-dehydrocholesterol, pre-vitamin D3, trans-cholecalciferol, toxisterol isomers, and oxygenated species. Limits are grade-dependent and are defined in the relevant pharmacopoeial monograph or customer specification. For stabilized feed-grade beadlets, the impurity profile also reflects the coating matrix and antioxidant system; potency retention over shelf life is monitored as a stability parameter in addition to release purity.

Identity is confirmed by HPLC retention time, ultraviolet absorption with a maximum near 264–265 nm, and infrared spectroscopy against a reference standard. HPLC-UV is the primary assay technique for cholecalciferol and related substances. Gas chromatography is used for residual solvents. Pharmaceutical and food grades are tested against USP and Ph. Eur. monographs for cholecalciferol. Feed-grade products are analyzed by methods aligned with regional feed-additive regulations and may include AOAC or ISO methods for premix stability.

When UV Lamp Output Drifts and Overirradiation Narrows the Quality Window

Industrial production of vitamin D3 is based on the photochemical ring-opening of 7-dehydrocholesterol to pre-vitamin D3, followed by thermal isomerization to cholecalciferol. Raw material selection focuses on 7-dehydrocholesterol purity, sterol peroxide value, and residual solvent profile. The sterol is typically obtained from wool-grease lanolin via cholesterol. High unsaturation makes the starting material prone to oxidation, so storage and charging must be conducted under inert gas.

The synthesis route is preferred because it produces cholecalciferol directly and can be integrated with chromatographic purification. 7-Dehydrocholesterol in a suitable solvent is irradiated with ultraviolet light in the 280–320 nm region. The conjugated steradiene undergoes photochemical electrocyclic ring opening to pre-vitamin D3. In a subsequent thermal step at approximately 60–80 °C, pre-vitamin D3 converts to cholecalciferol by an antarafacial [1,7]-sigmatropic hydrogen shift. The conversion is equilibrium-limited; yield depends on narrow wavelength control, short residence time distribution, and low dissolved oxygen.

Commercial photolysis is carried out in continuous falling-film or thin-film photoreactors equipped with temperature-controlled quartz-sleeved mercury lamps. Lamp intensity decay is monitored because a decline below the validated operating window increases residual 7-dehydrocholesterol, while excessive irradiation increases toxisterol formation. Dissolved oxygen is stripped with nitrogen before and during irradiation. After thermal isomerization, the crude product is concentrated, extracted, and crystallized from a suitable organic solvent. Pharmaceutical-grade material may require preparative HPLC or additional adsorption treatment to reduce oxidized impurities and residual sterols. Solvent recovery and retention are controlled as part of batch records.

Quality control and batch release include assay, related substances, residual solvents, moisture, appearance, and, where applicable, microbial and heavy metal limits. For stabilized feed grades, release also includes potency expressed as IU/g, dispersion behavior, beadlet particle size, and oxidative stability under accelerated test conditions. A batch is released only when the measured profile conforms to the registered specification and the reference standard response is within calibration limits.

Chemical modification of cholecalciferol is concentrated at the C3 hydroxyl group and the unsaturated triene system. Typical reactions include photochemical ring opening, thermal isomerization, oxidation, and esterification at C3 with acetic anhydride or other acylating agents. C3 esters are used as protected intermediates or for solubility control. The triene system is prone to rearrangement under acidic conditions and to oxidation or toxisterol formation under light or singlet oxygen. Hydroxylation at C25 and C1 produces 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3; these are manufactured by selected microbial transformations or multistep chemical routes and are commercial active metabolites for pharmaceutical and feed applications. Reaction conditions for derivatization are selected to minimize thermal input, exclude light, and use oxygen-free solvents. Catalysts, temperature, and solvent systems vary by route and are specified in the validated process.

Shelf-Life Boundaries Are Set by Accelerated Stability, Not by a Single Universal Value

For pure crystalline cholecalciferol, storage is normally specified in sealed containers at 2–8 °C, protected from light and moisture, with headspace nitrogen or argon. Humidity ingress should be avoided because condensed moisture can promote oxidation or hydrolysis. Stabilized feed beadlets are generally stored at or below 25 °C in closed original packaging; the assigned storage temperature is grade- and formulation-dependent. The product is light-sensitive, so amber glass or opaque lined packaging is used for small containers, and foil-laminate bags or fiber drums with polyethylene liners are used for larger quantities. Container compatibility includes HDPE and LDPE for many short-term storage situations; glass or epoxy-phenolic-lined metal containers are used where oxygen barrier performance is critical. Uncoated metal and containers with copper or iron contact should be avoided because trace metal ions accelerate oxidative degradation. Shelf life is assigned from long-term stability studies for each grade. Degradation signs include yellowing or browning, increase in related substances, assay below the release limit, characteristic off-odor, and caking in beadlet products.

What Regulatory Classification Applies to Neat Cholecalciferol?

Safety and toxicity information is concentration-dependent. For the neat substance, GHS classification typically includes acute oral toxicity and specific target organ toxicity after repeated exposure due to hypercalcemia and soft-tissue mineralization. The exact hazard statements and categories vary by supplier, regulatory region, and available data; the current safety data sheet must be used. Typical classifications of pure cholecalciferol may include Acute Tox. 2 (H300) or Acute Tox. 3 (H301) for the oral route, and STOT RE 1 (H372) for repeated exposure. Precautionary statements may include P260, P264, P270, P280, P301+P310, P308+P313, and P501; label text is jurisdiction-specific.

Published acute oral LD50 values for cholecalciferol in rats are in the low mg/kg body weight range, supporting classification as toxic by ingestion. Repeated or chronic intake produces hypercalcemia, calcification of soft tissues, and renal impairment. No harmonized binding occupational exposure limit is established for cholecalciferol in many jurisdictions; manufacturers may assign internal control limits for airborne dust. Production handling should use closed transfer systems, local exhaust ventilation, and HEPA-filtered vacuum cleanup. Dry sweeping is avoided. Operators should wear nitrile gloves, safety goggles, and suitable respiratory protection when dust levels exceed the internal exposure limit.

Production capacity and availability for Vitamin D3 are typically constrained by upstream cholesterol/lanolin refining, UV photochemical reactor throughput, and thermal isomerization capacity rather than by simple blending or dilution operations. Batch-to-batch consistency is maintained by controlling UV dose, thermal isomerization temperature and residence time, and final crystallization or spray-drying parameters. Catalog-grade material may be held as working inventory for standard feed and food concentrations; high-purity crystalline material and custom microencapsulated beadlet formulations are generally scheduled against confirmed orders because of the need to maintain low moisture and oxygen exposure in packaging. Lead time and minimum order quantity are determined by packaging configuration, final assay release, and destination documentation requirements. Direct-factory crystalline lots typically carry higher minimum order quantities than repacked feed-grade beadlets. Packaging options are selected to control moisture ingress, oxidation, and light-induced degradation: aluminum-laminated bags inside fiber drums are common for feed-grade powders, while pharmaceutical crystalline material may be packed in double polyethylene bags within aluminum foil laminate containers under inert gas. Release criteria generally include assay by HPLC, residual solvents by GC, heavy metals by ICP-MS, and microbial limits according to the target monograph or customer specification. Shipping and payment terms vary by product form and destination. Sea freight is used for bulk stabilized forms; air freight is used for time-sensitive small lots or temperature-sensitive crystalline material. Documentary collection or irrevocable letter of credit may be required for first transactions, with open account terms subject to supplier qualification and trade history.

What Drives the Raw Material Cost Structure of Vitamin D3?

The interpretation of raw material cost composition for Vitamin D3 is dominated by lanolin-derived cholesterol or alternative sterol feedstock, followed by UV irradiation energy, solvent recovery, and purification media. In the common lanolin route, cholesterol is extracted and purified to a 7-dehydrocholesterol intermediate; the subsequent step requires controlled UV exposure and thermal rearrangement to cholecalciferol. Compliant starting material cost can shift with wool scouring activity, sheep flock size, and competing demand for lanolin derivatives in personal care and pharmaceutical excipients. Solvent and energy inputs for chromatography, crystallization, and drying add further volatility, particularly when pharmaceutical-grade residual solvent limits are specified. Fluctuations in raw material prices are influenced by animal husbandry cycles, seasonal wool grease supply, alternate uses of cholesterol, energy costs, and logistics availability for temperature-sensitive intermediates. Regulatory reinspections at upstream facilities can temporarily reduce qualified feedstock supply and raise spot prices. Exchange-rate movements and ocean freight rates also affect delivered raw material costs in different producing regions. When feed-grade Vitamin D3 demand rises sharply, upstream lanolin/cholesterol allocation can tighten because the same feedstock pool supplies multiple sterol derivatives. Price differences among grades are primarily a function of activity concentration, purity, stability form, and certification package. A feed-grade spray-dried beadlet with a lower declared activity carries a lower unit price than a pharmaceutical crystalline grade, not only because of dilution but also because crystalline material requires more stringent control of residual solvents, related sterols, heavy metals, and chromatographic purity. Common feed-grade dry forms are stabilized beadlets in the range of 500,000 IU/g to 1,000,000 IU/g, while high-purity crystalline cholecalciferol is standardized near 40,000,000 IU/g. The same nominal Vitamin D3 activity can be sold at different prices depending on granule particle size distribution, antioxidant load, carrier system, and packaging certification such as FAMI-QS, ISO 22000, GMP, USP/EP monographs, or customer-specific DMF/CEP documentation. Packaging also creates price differences: oxygen-barrier aluminum foil packaging with desiccant and inert gas protection costs more than standard polyethylene-lined drums but supports longer shelf-life claims and lower oxidative degradation risk.

When 2026 Supply-Demand Balances Are Assessed Across Five Economies

Global supply and demand for Vitamin D3 are structurally asymmetric. Production is concentrated in China, with additional manufacturing in Europe and India. Chinese producers often operate integrated routes from lanolin/cholesterol or alternative sterol sources through UV conversion, giving the region a scale advantage in feed-grade material. European and Indian producers tend to serve pharmaceutical, food, and export-regulated segments where documentation continuity and analytical precision carry procurement weight. Demand is driven by animal feed fortification, dietary supplements, and pharmaceutical formulations. Feed-grade volume is the largest demand segment, but pharmaceutical and food grades require more intensive analytical release and generate higher unit value. In the United States, demand is import-dependent for feed and supplement grades. Importers rely on FDA-registered facilities, cGMP evidence, and in some cases DMF or CEP references. Price sensitivity is lower for high-purity grades than for commodity feed beadlets. The European Union maintains a narrower supplier base because REACH registrations and feed hygiene requirements limit entry; finished product manufacturers prioritize traceability, residual solvent data, and heavy metal reporting. Japan applies strict import specifications, with emphasis on assay reproducibility, storage stability, and documentation; smaller lot sizes may attract premium pricing. India shows rising demand for poultry and supplement pre-mixes, with procurement blending locally converted material and imports. China’s domestic oversupply in certain feed-grade formats tends to depress global spot prices, while environmental controls and energy costs can reduce production volume during peak periods and create price floors. For 2026, the Vitamin D3 price trend forecast is expected to be influenced by feedstock lanolin/cholesterol costs, energy and environmental compliance in China, and inventory cycles in the global feed industry. If upstream wool grease supply remains steady, feed-grade prices may stay range-bound with seasonal purchase spikes. If environmental controls restrict UV/solvent-based operations, export spot availability may tighten and raise prices. High-purity pharmaceutical grades are expected to remain less volatile, with pricing tied to contract terms, analytical documentation, and customer-specific qualification costs rather than short-term feed demand. Data sources and methodology for price trend assessment are based on published import/export trade statistics, customs data aggregates, manufacturer contract indices, and regional tender data where available. Forecast ranges are directional rather than exact price points because public transaction-level data for Vitamin D3 is limited and prices vary by activity concentration, form, packaging, and certification. The manufacturer’s internal cost model integrates feedstock indexes, energy inputs, solvent recovery costs, and logistics rates to produce budgeting scenarios.

Regulatory and trade developments affecting vitamin D3 supply chains

Recent market developments include continued consolidation among Chinese feed-grade producers and capacity additions directed at stabilized microencapsulated forms. The industry has also seen tightened demand for documentation on residual solvents and process-related sterols, especially for pharmaceutical-grade cholecalciferol sold into the European Union and Japan. Regulatory compliance updates affect labeling, assay expression, and stability studies. In the European Union, Vitamin D3 is subject to feed additive regulations and food supplements legislation; analytical methods for activity confirmation must align with pharmacopoeial or recognized standard methods. The United States requires importers to maintain FSVP and cGMP evidence for dietary supplement and animal feed applications. Japan imposes identity and purity requirements under food additive and feed safety frameworks, with re-testing often required at port. China’s feed additive registration system and environmental enforcement continue to influence the available production slate. Supplier response and mitigation includes maintaining multiple qualified feedstock sources, holding validated reference standards for assay, and issuing batch-specific certificates covering heavy metals, residual solvents, and microbiological data. For export-sensitive destinations, the manufacturer may pre-clear packaging materials and reserve qualified analytical capacity at ISO 17025-accredited laboratories. Where regulatory changes require additional marker compounds or stability data, the technical group updates the product specification and notifies affected customers before shipment. In cases of supply interruption, mitigation relies on converting unfinished intermediate inventory into finished goods, adjusting packaging configurations, and prioritizing pharmaceutical and food customers under existing contracts.

Application Fields & Grade Selection Guide — Vitamin D3

The application fields and grade matching guide for cholecalciferol is structured around the point at which the active is introduced, the oxygen and moisture load in downstream unit operations, and the compendial status accepted by the destination market. Crystalline cholecalciferol, oil-based concentrates, and beadlet or spray-dried forms do not behave as direct substitutes in direct compression, fat-filled milk fortification, or mineral-loaded premixes. Published data for this specific configuration is limited where a single carrier is expected to perform in all three systems.

Industry applications include dry dietary supplement manufacturing, food fortification, pharmaceutical and clinical nutrition, animal feed premix and aquaculture feed, and topical cosmetic formulations. In dry dietary supplement manufacturing, flowability, assay uniformity across a large batch, and compatibility with direct-compression excipients such as dicalcium phosphate and magnesium stearate are decisive. A free-flowing spray-dried or beadlet concentrate is preferred over neat oil because liquid cholecalciferol can create caking in high-speed tablet presses or capsule filling lines.

Food fortification lines introduce cholecalciferol into milk, edible oils, margarine, dairy powders, and dry beverage bases. The key processing constraint is dispersibility in aqueous or fat-continuous matrices without destabilizing the emulsion. Oil-based concentrates are typically added to fat-soluble systems; water-miscible beadlet forms are used for reconstituted milk and dry beverage bases. Infant formula and clinical nutrition formulations are the most restrictive, with analytical identity, total vitamin D3 content, sterol-related impurities, residual solvent class, and microbial limits evaluated against pharmacopoeial and regional pediatric nutrition standards rather than a single feed-grade criterion.

Animal feed premix operations impose aggressive oxidative exposure because cholecalciferol is blended with trace minerals, choline chloride, and limestone-based carriers. The beadlet matrix must resist attrition during pneumatic conveying and survive pelleting temperatures. Batch-to-batch variance in beadlet hardness can shift recoverable activity in finished feed; therefore the grade mapping should specify beadlet integrity, residual moisture, and peroxide value rather than assay alone. Pharmaceutical solid-dose and parenteral applications use crystalline or high-load concentrate forms where residual solvent profile, particle-size distribution, and compendial identity by high-performance liquid chromatography are release criteria. In topical cosmetic formulations, microbiological limits and heavy metal content are generally controlled, but the decisive downstream issue is often solubility in anhydrous oils or low-odor carriers.

Grade-to-application mapping and key parameters by application are consolidated in Table 1. The mapping is not static; a single finished-product format may need a higher-grade input if the manufacturing line introduces oxidative stress or if the destination market requires a stricter monograph.

Application Field	Typical Grade Alignment	Key Parameters by Application
Dry oral dosage forms (tablets, capsules, gummies)	USP or FCC grade; spray-dried or beadlet concentrate	Assay uniformity; particle-size distribution; loss on drying; flow index
Food fortification (dairy, oils, powdered beverages)	Food grade conforming to FCC or regional food additive standards	Dispersibility; carrier type; peroxide value; heavy metal limits
Infant formula and clinical nutrition	Pharmaceutical/food grade conforming to Ph. Eur., USP, and destination pediatric nutrition directives	Total sterol profile; residual solvents; microbial limits; assay stability in finished matrix
Animal feed premix and aquaculture feed	Feed grade; beadlet or spray-dried	Beadlet hardness; attrition resistance; residual moisture; peroxide value; compatibility with choline chloride and trace minerals
Topical cosmetic formulations	Cosmetic grade or USP depending on regional requirements	Heavy metals; microbial limits; oil solubility; odor profile

How Does Grade Selection Proceed Through Five Decision Gates?

How to select the right grade proceeds through five decision gates, beginning with application definition and ending with sample validation. The final release standard is subject to internal quality control criteria and customer requirements when multiple monographs overlap.

Step 1: Define Application establishes whether the active is dry-blended, dissolved in oil, sprayed onto a carrier, or incorporated into a heat-processed pediatric product. This determines physical form, carrier type, and minimum assay concentration.

The second gate, Step 2: Identify Regulatory Requirements, maps the formulation against the required pharmacopoeial monograph, food chemical codex, feed additive regulation, or regional cosmetic standard. If a monograph applies, its test methods and acceptance criteria define the minimum release profile.

Third, Step 3: Evaluate Purity Needs compares residual solvent class, heavy metal limits, peroxide value, and related sterol or isomer content against the intended patient or animal population. High-load concentrates cannot be selected solely on assay; matrix-derived impurities and carrier residues must be reviewed.

The fourth gate is Step 4: Consider Volume & Budget. Procurement volume, storage conditions, and batch demand are matched against available packaging and stability data. Larger production lots reduce testing frequency but may require more stable antioxidant-stabilized carriers or lower initial moisture specifications.

Final validation occurs at Step 5: Request Sample for Validation. A sample is requested and tested in the actual mixing, tableting, filling, or extrusion line to confirm blend uniformity, recovery after processing, and appearance before release. Acceptability is determined against the release criteria defined in the previous gates.

Quality compliance and certification support for vitamin D3 is organized around three control layers: quality management certification, product-specific certificate compliance, and customer-linked analytical documentation. A lot release file therefore requires alignment between the site-level certified quality management system, the applicable pharmacopoeial or regulatory monograph, and the document set required by the buyer.

The production site operates under a quality management system certified to ISO 9001:2015. For food and dietary supplement applications, the food safety management system is operated under ISO 22000:2018 or FSSC 22000 where the site scope includes those product forms. Dietary supplement applications in the United States are additionally managed under current GMP for dietary supplements, 21 CFR Part 111, where the material is supplied as a dietary ingredient. Feed-grade cholecalciferol is controlled under feed hygiene rules, with certification or audit alignment to FAMI-QS and Regulation (EC) No 183/2005 where applicable to the placing on the EU market. Pharmaceutical-grade material is manufactured under current good manufacturing practice expectations aligned to ICH Q7 and, depending on registration status, 21 CFR Part 210/211. Certification scope is not uniform across all product forms; it is linked to the site, the intended end-use, and the regulatory registration.

Release limits for assay, related sterols, residual solvents, and elemental impurities are grade-dependent and application-specific; no universal specification applies to all forms. Vitamin D3 may be released against USP–NF Cholecalciferol, Ph. Eur. Colecalciferol, BP, or FCC monographs, or against customer-specific specifications where the release limits are agreed in a supply contract. Kosher and Halal certificates are available for production campaigns that meet the relevant religious authority requirements. BSE/TSE statements are provided because the commercial route from wool grease lanolin-derived cholesterol can attract supply chain documentation requests for food, feed, and pharmaceutical use. Statements concerning residual solvents, GMO status, and irradiation are issued where required by the market authorization or customer questionnaire.

The standard document package for a released vitamin D3 lot includes the certificate of analysis, safety data sheet, and origin-related statements. Additional documents are issued depending on the market registration and customer audit requirements. The following matrix lists typical documents and their reference basis.

Document type	Content or control point	Reference basis
Certificate of Analysis	Assay, related sterol profile, residual solvents, heavy metals, appearance, and specific tests agreed in the specification	Pharmacopoeial monograph or customer specification
Safety Data Sheet	Hazard communication, storage, transport, and exposure control information	GHS implementation under Regulation (EC) No 1272/2008 or 29 CFR 1910.1200
BSE/TSE statement	Raw material origin and production process statement	Applicable BSE/TSE regulatory guidance or customer questionnaire
Allergen and GMO statement	Confirms raw material and processing aids do not introduce declared allergen or GMO concern	Food safety management system scope
Residual solvent report	Solvent residues from crystallization and extraction steps	ICH Q3C or pharmacopoeial method
Stability data or retest information	Long-term and accelerated data for supported packaging configurations	ICH Q1A/Q1E where applicable for pharmaceutical-grade lots
Elemental impurity report	Elemental impurity testing according to route risk	ICH Q3D or pharmacopoeial chapter

When a Buyer Engages the Manufacturer for Lot-Specific Supply

The stable production capacity and flexible business cooperation plan is built on campaign scheduling rather than continuous lot-by-lot processing. The material moves through cholesterol purification, 7-dehydrocholesterol formation, photochemical conversion, thermal isomerization, and final purification. Because the photochemical reactor and solvent recovery train are shared across cholecalciferol and related sterol campaigns, the master production schedule allocates capacity against confirmed orders, forecast demand, and raw material availability. A flexible supply plan is maintained by holding approved intermediates and by reserving reactor time for shorter finalization campaigns. Buyers are informed when compendial release testing or additional customer-specific analytical work changes the confirmed lead time.

Raw material selection for lanolin-derived cholesterol focuses on sterol content, iodine value, and the absence of heavy metal and pesticide residues that would increase downstream purification burden. The process route uses UV photoconversion of 7-dehydrocholesterol to pre-vitamin D3, followed by thermal isomerization to cholecalciferol. Key control points include UV lamp spectral output, irradiation intensity, solvent viscosity, residence time, and the thermal isomerization temperature profile. Incomplete conversion raises pre-vitamin D3, tachysterol, and lumisterol-related impurity levels, which are then removed by solvent crystallization and, where required, preparative chromatography or molecular distillation. Batch consistency is monitored by HPLC assay and related substance profile against the selected monograph. Release occurs only after the batch meets internal release limits and the buyer’s specification. Production capacity is typically constrained by the photochemical reactor train and solvent recovery capacity, not by raw material availability alone.

Sample application is initiated through the manufacturer’s quality assurance or supply coordination contact. The applicant states the intended application, target market, required specification, and sample quantity. The manufacturer reviews whether the requested vitamin D3 form—crystalline powder, oily solution, spray-dried, or beadlet—is appropriate for the stated use. Samples are supplied from retained lots or drawn from a current campaign; retained samples are released only after confirming that the container closure has not been compromised and that the sample remains within retest date. Sample packaging uses amber glass or foil-laminated containers with nitrogen headspace where required, and the label includes product name, lot number, retest date, and a statement limiting use to laboratory evaluation. A safety data sheet and a sample dispatch note are provided with the shipment. For customer-specification alignment or custom-grade evaluation, a confidentiality agreement may be required before the sample is released.

Three cooperation modes are used for vitamin D3 supply. Lot-spot purchasing is the simplest mode: the buyer selects an available lot and receives the lot-specific CoA before or after dispatch according to the agreed order flow. Call-off supply operates under a framework agreement with an agreed annual quantity; the manufacturer reserves the material and releases partial lots according to the buyer’s delivery schedule, with each partial lot accompanied by its own CoA and supporting documents. Custom manufacturing mode is used when the buyer requires a different assay concentration, antioxidant system, carrier oil, particle size, packaging configuration, or release test set. Custom orders undergo technical feasibility review because changes to the antioxidant type or carrier oil can affect chemical stability and because customer-specific methods may require method alignment or transfer. Custom manufacturing carries longer lead time due to packaging qualification, analytical alignment, and, where applicable, stability confirmation. In all modes, the release standard remains governed by the selected pharmacopoeial or regulatory monograph and the agreed customer specification.

Current research and development hotspots in cholecalciferol (vitamin D3; CAS 67-97-0) concentrate on stabilizing the conjugated triene system against oxidation, photoisomerization, and acid-catalyzed rearrangement in complex premixes. The most intensive work addresses interaction between cholecalciferol and transition-metal ions such as iron and copper in feed premixes, where direct contact with choline chloride and acidic carriers accelerates potency loss. Industrial mitigation routes centre on spray-cooled fat matrices, crosslinked gelatin or modified starch beadlets, and gum acacia/maltodextrin systems; the most appropriate barrier chemistry depends on the redox potential and moisture load of the target premix rather than on a universal encapsulation format.

Emerging application development is moving beyond conventional oily dilutions and feed beadlets. Plant-based dairy alternatives, low-fat high-protein beverages, parenteral nutrition lipid emulsions, and aquaculture formulations require cold-water-dispersible, shear-stable delivery forms with narrower particle size distribution. Non-animal cholecalciferol from lichen-derived material has entered the human nutrition market but remains differentiated by source documentation and price structure; published technical data on long-term stability in complex food matrices for this specific source are limited. Research also continues on high-load direct-compression granules and secondary combinations with vitamin K2, where dissolution and content uniformity are controlled by granulation end-point and lubricant selection rather than by active content alone.

The main unresolved technical bottleneck in production is control of the photoisomerization cascade from 7-dehydrocholesterol to pre-vitamin D3, tachysterol, and lumisterol. In commercial photochemical reactors, the ratio of these related compounds is a function of emission wavelength, irradiation time, temperature, and solvent quality. Development of continuous-flow photochemical reactors with narrow UV bandwidth has reduced tachysterol content in pilot configurations, but published reactor-scale quantum yield data are limited and highly equipment-specific.

What Shapes the 3–5 Year Market Trajectory for Vitamin D3?

Demand over the next three to five years is expected to expand most visibly in animal nutrition and food fortification, driven by regional minimum fortification requirements and feed additive authorisations under Regulation (EC) No 1831/2003. Human supplement growth is influenced by bone health and immune-support positioning, while food fortification levels remain constrained by product-specific maximum limits under Regulation (EC) No 1925/2006 and Directive 2002/46/EC. Aggregate market growth projections vary widely by segment and geography; published values should not be directly transferred to a single production site or grade without baseline inventory and capacity adjustments.

Technological evolution is shifting toward lower-solvent photoconversion, solvent recovery in the isolation and purification of the photoirradiated reaction mass, and supercritical fluid chromatography for impurity fingerprinting. Continuous processing is being evaluated for improved batch consistency and lower specific energy input in the UV conversion step. In downstream formulation, the trend is toward non-gelatin, plant-derived beadlets, reduced overage requirements through tighter premix redox control, and water-dispersible powders with defined sedimentation and reconstitution behavior.

Sustainability and green chemistry issues in cholecalciferol production are not limited to raw material source. Lanolin-derived routes benefit from the use of a wool scouring by-product, but the process carries solvent and energy burdens in extraction, purification, and photochemistry. Current green chemistry development focuses on solvent substitution, recovery loops in saponification and purification, energy integration of UV reactors, and reduction of chlorinated solvent use. Bio-based and fermentation-derived routes remain an active research topic but are not yet equivalent to established lanolin-based capacity in large-scale cost and regulatory documentation.

When Formulation Limits Are Reached: Technical Support and After-Sales Framework

Technical consultation services address the point at which a customer's premix, tablet, emulsion, or finished dose form shows assay drift, segregation, or color change. The manufacturer's technical group reviews incoming certificate-of-analysis data against the application matrix, including residual solvents by USP Chapter 467, assay by USP Chapter 621, peroxide value, acid value, isomer distribution, and microbial limits per USP Chapters 61/62. If the application involves a novel source or claim, documentation support is provided for regulatory evaluation, but final acceptance remains subject to the applicable national or regional authority.

Application optimization support includes pilot-scale formulation trials on equipment such as ribbon blenders, planetary mixers, high-shear granulators, and spray-cooling systems. Particle size distribution may be measured by laser diffraction under ISO 13320:2020, and flowing properties by bulk density, tapped density, and angle of repose methods. Stability screening typically follows compendial and ICH Q1A(R2) conditions, including long-term storage at 25°C/60% RH and accelerated storage at 40°C/75% RH. Where premix activity loss is observed, the technical group supports overage calculation based on redox potential, trace-metal content, choline chloride concentration, and expected storage duration; the required overage is grade- and formulation-specific and cannot be supplied as a fixed nominal value.

After-sales commitments are built on batch traceability from raw material reception through blending, encapsulation, packaging, and dispatch. Each production batch is subject to retention sampling and documented change control under an internal quality system aligned with ISO 9001:2015 and food safety management aligned with ISO 22000:2018. If a field failure is confirmed, root-cause investigation proceeds through retained samples, production log review, and re-analysis; corrective action is defined in consultation with the customer's quality unit. Specification changes, process changes, or raw material source changes are communicated to affected customers before implementation according to the agreed change-notification clause in the supply agreement. The manufacturer maintains customer-specific limits on the certificate of analysis and can align analytical methods with compendial, customer, or internal methods, provided the method's specificity and system suitability are demonstrated at release and on retained samples.

Vitamin D3 (Cholecalciferol) Manufacturing and Industrial Supply

Cholecalciferol (vitamin D3) is manufactured through a controlled photochemical process beginning with 7-dehydrocholesterol of wool sterol origin. The crystalline active is obtained after UV irradiation in the 280–320 nm range followed by thermal isomerization at 60–80°C and preparative purification. The production facility supplies the active as crystalline cholecalciferol, spray-dried powders, beadlet forms, and oil-based concentrates for downstream food, feed, pharmaceutical, and nutritional formulation.

Manufacturing Scope and Product Forms

Production campaigns are segregated by grade. Food fortification grades are produced under FDA 21 CFR Part 117 and ISO 22000 requirements; pharmaceutical-grade material follows ICH Q7 with full master batch records. Each final packed lot is released after identity, potency, particle-size distribution, moisture, and elemental impurity testing.

Product Form	Typical Potency	Primary Processing Route	Industrial Application
Crystalline cholecalciferol	40,000,000 IU/g	Photochemical ring-opening, thermal isomerization, preparative chromatography	Oil-based concentrates, pharmaceutical stock solutions, high-potency formulations
Spray-dried powder	100,000 IU/g	Aqueous emulsion with modified starch and acacia, spray drying	Dairy and plant-based beverage fortification, powdered nutritional products
Feed beadlet	500,000 IU/g	Fluidized-bed coating onto matrix particles	Animal premix, complete feed, aquaculture diets
High-potency beadlet	1,000,000 IU/g	Agglomeration and cross-linked matrix formation	Tablets, two-piece hard capsules, dry powder blends
Oil concentrate	1,000,000 IU/g	Dilution of crystalline active in medium-chain triglycerides under nitrogen	Softgels, edible oil fortification, infant formula oil phase

Where Stabilized Dry Cholecalciferol Is Critical in Feed Premix Systems

The limiting problem in broiler, swine, and aquaculture premix manufacturing is oxidative and moisture-driven degradation caused by contact with choline chloride and trace mineral sulfates. Cross-linked beadlet forms with a gelatin-sucrose or starch matrix reduce exposed surface area and limit migration of water-soluble metal ions into the vitamin phase. In production-scale blending, a 500,000 IU/g feed beadlet was blended at 2 kg/t in a double-ribbon mixer with a fill ratio of 0.6 and achieved a coefficient of variation below 5% after 8 min, measured by AOAC 2016.05. Pellet durability trials on a 3 mm die with conditioning at 75°C showed no significant assay loss when retention time was kept below 30 s and the beadlet was added after the conditioner. Published data for prolonged conditioning above 80°C is limited.

In dairy and plant-based beverage fortification, spray-dried vitamin D3 powders with Dv50 between 100 µm and 180 µm disperse under high-shear mixing at 8,000–12,000 rpm without forming surface oil films. The powder bulk density is generally 0.45–0.65 g/cm³, which supports gravimetric dosing accuracy in high-speed filling lines. Stability in UHT-treated milk processed at 135–150°C for 2–5 s depends more on oxygen headspace than on thermal input; dissolved oxygen below 1.0 mg/L is recommended in the filled package.

Pharmaceutical-Grade Crystalline Cholecalciferol and Direct Compression Requirements

For tablet and hard capsule operations, crystalline material is usually pre-blended with microcrystalline cellulose and silicon dioxide before tableting. Direct compression requires a feed beadlet or spray-dried granule because the crystalline form has low bulk density and poor compactibility. The 1,000,000 IU/g high-potency beadlet is used in dry granulation and tableting; finished dosage forms are evaluated by content uniformity per USP 905 and friability per USP 1216. Batch-to-batch particle-size distribution is controlled by sieve analysis per USP 786 or laser diffraction per ISO 13320. Softgel fills use oily concentrates standardized to 1,000,000 IU/g in medium-chain triglycerides or sunflower oil; fill mass is calculated from the assay of each lot rather than nominal potency.

When Cholecalciferol Enters Edible Oil and Lipid Matrices

Fortification of margarine, cooking oil, and butter involves dilution of crystalline cholecalciferol or an oil concentrate into a lipid phase under nitrogen. Solubility of cholecalciferol in medium-chain triglycerides at 25°C is sufficient to prepare a 1,000,000 IU/g stock solution, but heating to 40–50°C reduces viscosity and shortens blend time in 500–2,000 L oil tanks equipped with propeller agitators. Oxygen exclusion at the dilution step is critical because oxidation of the conjugated triene system is accelerated by trace copper and iron above 0.1 ppm. Final oil blends are monitored by inline UV absorption at 265 nm after a 10 min circulation loop.

What Analytical Controls Govern Batch Release?

Release decisions are based on orthogonal identity and purity data. HPLC with UV detection at 265 nm is routine; peak area is compared against a USP reference standard. The method follows USP 571 for vitamin D, with system suitability resolution greater than 1.5 between cholecalciferol and pre-cholecalciferol. Related sterols are quantitated by area normalization. Elemental impurities are controlled by ICP-MS or atomic absorption according to USP 232 and USP 233 after an ICH Q3D risk assessment. Residual solvents in crystalline material are controlled by headspace GC according to Ph. Eur. 2.4.24. Statistical process control charts track potency and particle size with control limits at 3 sigma; retained samples are stored for 36 months or 12 months beyond assigned shelf life.

Control Parameter	Method/Standard	Typical Acceptance Basis
Potency	USP 571, Ph. Eur. 2.2.29	95.0–105.0% of label claim for formulated forms
Related sterols and degradation products	USP 571	Reported as area percent; individual unknown controlled by product monograph
Particle size distribution	ISO 13320	Dv50 within release range for each physical form
Moisture / loss on drying	Ph. Eur. 2.2.32	≤ 5.0% for spray-dried and beadlet forms; crystalline material lower
Elemental impurities	USP 232, USP 233	Meets ICH Q3D oral limits
Microbial limits	USP 61, USP 62	TAMC ≤ 1,000 CFU/g, TYMC ≤ 100 CFU/g, specified pathogens absent

For moisture-protected export shipments, crystalline cholecalciferol is filled into aluminum foil-laminated bags with a foil thickness of not less than 20 µm, placed inside HDPE drums, and sealed under vacuum or nitrogen. Residual oxygen in the sealed headspace is controlled below 1.0% v/v. Feed-grade beadlets are packed in polyethylene-lined multi-wall paper bags or fiber drums with a water vapour transmission rate at or below 0.5 g/m²/day. Lot-specific labels carry storage conditions, production date, retest date, and net mass. Silica gel desiccants are inserted for tropical climate shipments.

Scale-Up Trials and Analytical Method Transfer for Industrial Buyers

Technical service is structured around process fit, not generic product substitution. A pilot line equipped with a 200 L high-shear mixer, a 1,000 L double-ribbon blender, and a laboratory spray dryer supports homogenization studies. For feed mill transfers, the recommended procedure is to first run a 1:1000 premix dilution in the buyer's mixer geometry and measure vitamin recovery at 5 sampling points. The analytical group supports method transfer per USP 1225 and ICH Q2(R1), including precision and intermediate precision runs at 3 concentration levels. Stability data packages follow ICH Q1A(R2) for pharmaceutical applications and real-time studies at 25°C/60% RH for feed and food grades.

Procurement and Inventory Structuring for Feed and Food Manufacturers

Long-term demand planning is supported through fixed batch sizes, toll conversion options, and safety-stock inventory held at the manufacturing site. Because the crystalline active has a recommended storage temperature of 2–8°C and a retest window tied to the real-time stability protocol, procurement can schedule quarterly releases rather than spot purchases. Batch certificates include potency, related substances, elemental impurities, microbial limits, residual solvents, and regulatory statements. Distributors receive full lot traceability, country-specific documentation, and sealed original-pack formats that allow unchanged re-sale under correct storage conditions. The commercial model is direct, with full audit trail from raw material lot to packed goods; no release occurs without a certificate of analysis issued by the plant's quality unit.

Industrial FAQ